recognized standard clinical outcome assessment. In March: Tiziana announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences , that. | April 26, 2023
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel
Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced plans to investigate intranasal foralumab for the treatment of Long COVID, work which is supported by.
Tiziana Life Sciences (TLSA) to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.